Sigma Planning Corp Buys 630 Shares of GSK plc (NYSE:GSK)

Sigma Planning Corp increased its stake in shares of GSK plc (NYSE:GSK) by 1.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,819 shares of the pharmaceutical company’s stock after buying an additional 630 shares during the quarter. Sigma Planning Corp’s holdings in GSK were worth $1,178,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Sunbelt Securities Inc. boosted its stake in shares of GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares in the last quarter. Mesirow Financial Investment Management Inc. lifted its holdings in GSK by 2.0% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock valued at $682,000 after purchasing an additional 323 shares during the last quarter. Rehmann Capital Advisory Group boosted its position in GSK by 6.3% in the third quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock valued at $232,000 after buying an additional 332 shares in the last quarter. Investment Partners Asset Management Inc. grew its stake in GSK by 2.3% during the third quarter. Investment Partners Asset Management Inc. now owns 15,559 shares of the pharmaceutical company’s stock worth $636,000 after buying an additional 344 shares during the last quarter. Finally, Bond & Devick Financial Network Inc. increased its holdings in shares of GSK by 5.4% during the third quarter. Bond & Devick Financial Network Inc. now owns 7,830 shares of the pharmaceutical company’s stock worth $320,000 after buying an additional 400 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Price Performance

Shares of GSK stock opened at $37.03 on Tuesday. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The firm has a market cap of $76.74 billion, a price-to-earnings ratio of 23.29, a PEG ratio of 1.12 and a beta of 0.64. The stock has a 50-day moving average price of $34.67 and a 200 day moving average price of $37.32. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Research analysts expect that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be paid a dividend of $0.3932 per share. This is a positive change from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 annualized dividend and a yield of 4.25%. GSK’s dividend payout ratio (DPR) is presently 98.74%.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on GSK shares. Morgan Stanley began coverage on GSK in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Finally, Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Seven analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.